Second case of rare mpox strain discovered in traveller
A case of the Clade 1 strain of mpox has been confirmed in a patient in Queensland's Metro South Hospital and Health Service region, the state's health body said.
The patient is believed to have acquired mpox overseas before arriving in Australia, state Health Minister Tim Nicholls said.
"Contact tracing has been occurring, and the community can be assured that exposure to members of the community has been very limited, and the public should not be concerned," he said on Saturday.
The detection is the second incidence of the mpox strain reported in Australia after a returned traveller tested positive for the virus in NSW in May.
Mpox is a viral infection that typically displays mild symptoms of fever, headache, muscle aches, swollen lymph nodes or fatigue, followed by a skin rash or lesions.
The disease does not easily spread between people and mostly occurs through very close or intimate contact with someone infected.
Groups at higher risk of infection include sexually active gay, bisexual or other men who have sex with men and their partners.
Health authorities say vaccinations for pre- and post-exposure to the disease are effective and are available for free through sexual health clinics and general practitioners.
#mpox remains a public health emergency of international concernThe announcement follows the fourth meeting of the IHR Emergency Committee regarding the upsurge of mpox. The Committee advised the Director-General @DrTedros to extend the public health emergency of international… pic.twitter.com/fPP3duWuuh
— World Health Organization (WHO) (@WHO) June 9, 2025
Two doses of vaccine are needed for optimal protection, with vaccination reducing the risk of infection and severe disease.
The World Health Organization declared the mpox outbreak a public health emergency of international concern in August 2024.
The disease was first detected in Australia in 2022, with the number of cases spiking to more than 1400 in 2024, according to Australia's National Notifiable Disease Surveillance System.
There have been about 150 confirmed cases of mpox in 2025.
Men make up the majority of reported notifications, accounting for more than 1700 of all confirmed cases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Calls to make low-cost IVF more accessible in Australia
Vikki Mai Murphy always knew she wanted to be a mum but after months of negative pregnancy tests she and her partner Sean realised they would need some extra help. Following a round of intrauterine insemination (IUI), where prepared sperm is placed directly into a woman's uterus, Ms Murphy was thrilled to finally see a positive result for the first time. But almost eight weeks later, she discovered the pregnancy was ectopic and would have to be removed. In the resulting surgery she lost one of her fallopian tubes and doctors told her she would need to undergo IVF in order to successfully fall pregnant in future. "I just bawled and kept asking if I could still have my babies ... it just crushed me," Ms Murphy told AAP. The couple began to explore their IVF options and quickly realised the cost per round would be between $10,000 and $15,000. "We both just decided we wanted to throw everything at it and worry about the costs later," Ms Murphy said. For many people hoping to become parents, cost-of-living pressures are deterring them from fertility treatment. With Australia posting a record-low fertility rate in 2024, experts say low-cost IVF options will be crucial to addressing the decline in births. The average number of children born per woman was 1.51 in 2024, well below the 1.8 in 2014. In 2022, almost 109,000 IVF cycles were performed resulting in the birth of 20,058 babies. Almost half of Australians surveyed by Connect IVF said fertility services were not affordable. Connect IVF was one of the few affordable clinics in an industry that had been driven by a wave of corporatisation, director Brendan Ayres said. "(Our clinics) see a broad section of Australians and we get a disproportionate number of people from lower socioeconomic groups who need fertility treatment," he said. "We also have a number of patients who have been to other clinics and paid tens of thousands of dollars without success and are at their financial wits' end." Ms Murphy discovered Connect IVF by a chance internet search and the clinic was able to accommodate her for her next menstrual cycle. "The cost was substantially lower than other clinics because they bulk-billed the IVF cycle," she said. "It also allowed us to pay for a private obstetrician during my pregnancy, which we wouldn't have been able to afford if we'd had to pay up to $15,000 for the IVF." Ms Murphy ended up with four embryos from the round, which led to her three-year-old son Beau and one-year-old daughter Maia. "I love being a mum. It was such a journey and if I could have just looked into the future and seen my babies it would have made such a difference," she said. "People might think if they pay more money there might be more chance of having a baby, but I have friends who have paid thousands more than us with no success." While the Australian government supports parts of IVF through Medicare, it was not linked to the consumer price index, meaning the gap increased over time, Mr Ayres said. "Australia is a world leader in the technology of IVF but the funding hasn't followed," he said. "There also needs to be additions to Medicare item numbers to expand to all areas such as donor IVF which currently isn't covered."
Yahoo
a day ago
- Yahoo
Spike in ADHD medication reports
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said.
Yahoo
a day ago
- Yahoo
Women's symptoms 'overlooked' in menopausal stages
Women going through perimenopause are experiencing debilitating hot flushes and night sweats that are often untreated, as a study reveals the prevalence of symptoms during hormonal transitions. Perimenopause is a transitional period before menopause, where levels of oestrogen begin to decrease, bringing with it a range of symptoms. A first of its kind study of more than 5500 women by Monash University published in The Lancet Diabetes and Endocrinology examined the similarities and differences in symptoms across the stages of menopause. Almost 40 per cent of perimenopausal women in the study experienced debilitating vasomotor symptoms (VMS) such as hot flushes and night sweats. While it was already known that VMS symptoms were typical in menopause, the study showed a new onset was highly specific to perimenopause, senior author Susan Davis said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. "While other symptoms might emerge in the perimenopausal stage, they lack specificity to that stage as these other symptoms are also common in pre-menopausal women." A major finding in the study was that women with regular cycles but changed menstrual flow and VMS who are classified as pre-menopausal have a similar severity of symptoms as perimenopausal women. "This finding supports the likelihood of perimenopause commencing before menstrual cycles vary by at least a week, and that women whose periods have become much heavier or much lighter and who also have VMS should be considered as having entered their perimenopause," Professor Davis said. The research was expected to transform women's health treatment, particularly in menopause, which had been overlooked for too long, Monash Women's Health Alliance chair Jill Hennessy said. "Too many go untreated for debilitating symptoms like hot flushes and night sweats," she said. "By defining the symptoms that truly mark this transition, this study empowers women and clinicians alike with better knowledge and tools to improve women's health and wellbeing." The study authors hoped the findings would improve how medical professionals identified and managed transitions in menopause. Many women were overlooked in being classified within a menopausal stage if they had regular cycles or no longer menstruated due to a hysterectomy, first author Rakib Islam said. "Our findings support a more symptom-based approach, enabling earlier recognition of perimenopause and more timely care," he said.
